REGN22530 for Primary Open Angle Glaucoma or Ocular Hypertension
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Recruiting
Phase 1
Phase 2
Interventional Study
Primary Open Angle Glaucoma (POAG)
Ocular Hypertension (OHT)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 271 (estimated)
- Sponsor
- Regeneron Pharmaceuticals · Industry
Who this trial is looking for
This trial is looking for adults with primary open angle glaucoma or ocular hypertension. Participants will receive an experimental drug called REGN22530 to see how it affects eye pressure and any side effects it may cause.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with ocular hypertension or primary open angle glaucoma.
- I have a best-corrected visual acuity of at least 20/200 in the study eye.
- I have a best-corrected visual acuity of at least 20/80 in the non-study eye.
- I have had my eye lens implanted for at least 3 months.
- I have clear eye media and can undergo imaging.
You may not be able to join if
- I have glaucoma or ocular hypertension caused by other medical issues.
- I have a cataract that may need surgery during the trial.
- I have significant scarring in my cornea affecting eye pressure measurements.
- I have had certain glaucoma surgeries in the past.
- I have had laser treatment in the past 6 months.
- I have had certain types of cyclophotocoagulation in the past year.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension. REGN22530 is an experimental drug that is designed to bind with a protein in the eye that has been shown to cause a buildup of fluid inside the eye and cause increased Intraocular Pressure (IOP).
REGN22530 attaches to this protein an…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria:
1. Diagnosis of OHT or POAG of mild to moderate severity as described in the protocol
2. Best-Corrected Visual Acuity (BCVA) of ≥35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of better than or equal to 20/200) in the study eye on day 1
3. …
Contacts